Autobio(SH:603658) Sou Hu Cai Jing·2025-05-31 02:51Core Viewpoint - Antu Biology (603658) is actively managing idle fundraising through cash management strategies, indicating a focus on optimizing financial resources while maintaining operational integrity [1][2]. Group 1: Company Performance - As of May 30, 2025, Antu Biology's stock closed at 39.04 CNY, down 0.69% from the previous week [1]. - The company's total market capitalization is 22.308 billion CNY, ranking 7th in the medical device sector and 680th among all A-shares [1]. Group 2: Institutional Research Highlights - During the investor reception event on May 22, 2025, it was revealed that Antu Biology plans to install 72 units of the X-1 production line and 82 units of the A-1/B-1 production lines in 2024 [1][4]. Group 3: Company Announcements - Antu Biology's board approved the use of up to 1.7 billion CNY of idle fundraising for cash management, focusing on safe and liquid principal-protected products with a maximum holding period of 12 months [2]. - The company plans to invest 250 million CNY in structured deposits and large certificates of deposit, with expected yields between 2.05% and 2.90% [1][2]. - As of March 31, 2025, the company's cash reserves were 232.8309 million CNY, with the cash management amount representing 141.73% of the cash reserves [2].